Table 1.
Baseline Patient and Lesion Characteristics and Postprocedure Medical Therapy Between Patients With and Without Diabetes Mellitus (DM).a
| All | DM | No DM | p | |
|---|---|---|---|---|
| Patient characteristics | n=1906 | n=1084 | n=822 | |
| Age, y | 66.5±9.9 | 66.2±9.6 | 66.8±10.3 | 0.219 |
| Men | 1469 (77.4) | 860 (79.3) | 609 (74.9) | 0.024 |
| Race | ||||
| White | 1344 (70.8) | 718 (66.2) | 626 (77.0) | <0.001 |
| African American | 328 (17.3) | 193 (17.8) | 135 (16.6) | |
| Hispanic | 178 (9.4) | 145 (13.4) | 33 (4.1) | |
| Other | 47 (2.5) | 28 (2.6) | 19 (2.3) | |
| Rutherford category | ||||
| 1 | 184 (9.7) | 91 (8.4) | 93 (11.4) | <0.001 |
| 2 | 93 (4.9) | 40 (3.7) | 53 (6.5) | |
| 3 | 913 (48.1) | 453 (41.8) | 460 (56.6) | |
| 4 | 273 (14.4) | 164 (15.1) | 109 (13.4) | |
| 5 | 434 (22.9) | 336 (31.0) | 98 (12.1) | <0.001 |
| Critical limb ischemia | 707 (37.3) | 500 (46.1) | 207 (25.5) | <0.001 |
| Coronary artery disease | 1238 (65.3) | 789 (72.8) | 449 (55.2) | <0.001 |
| Prior MI | 441 (23.3) | 285 (26.3) | 156 (19.2) | <0.001 |
| Chronic kidney disease | 345 (18.2) | 274 (25.3) | 71 (8.7) | <0.001 |
| Heart failure | 329 (17.3) | 238 (22.0) | 91 (11.2) | <0.001 |
| Hypertension | 1731 (91.3) | 1048 (96.7) | 683 (84.0) | <0.001 |
| Hyperlipidemia | 1623 (85.6) | 993 (91.6) | 630 (77.5) | <0.001 |
| LDL, mg/dL | 82.0±34.8 | 77.3±34.4 | 88.5±34.3 | <0.001 |
| Ankle-brachial index | 0.68±0.23 | 0.68±0.24 | 0.69±0.22 | 0.184 |
| Lesion characteristics (per limb) | n=2426 | n=1358 | n=1068 | |
| Target vessels | ||||
| Femoropopliteal | 1969 (81.2) | 1028 (75.7) | 941 (88.1) | <0.001 |
| Infrapopliteal | 424 (17.5) | 313 (23.1) | 111 (10.4) | <0.001 |
| Multivessel diseaseb | 660 (27.2) | 393 (28.9) | 267 (25.0) | 0.030 |
| Iliac intervention | 234 (9.7) | 92 (6.8) | 142 (13.3) | <0.001 |
| Infrapopliteal runoff | 2.1±0.8 | 2.0±0.8 | 2.2±0.8 | <0.001 |
| Vessel diameter, mm | 4.9±1.1 | 4.8±1.2 | 5.1±1.0 | <0.001 |
| Lesion length, mm | 136.8±99.4 | 134.8±98.9 | 139.2±100.0 | 0.366 |
| Chronic total occlusions | 1259 (51.9) | 699 (51.5) | 560 (52.4) | 0.638 |
| Heavy calcificationc | 1190 (49.5) | 704 (51.8) | 486 (45.5) | 0.002 |
| Endovascular treatment | ||||
| Angioplasty | 2113 (87.1) | 1192 (87.8) | 921 (86.2) | 0.261 |
| Atherectomy | 1046 (43.1) | 574 (42.3) | 472 (44.2) | 0.341 |
| BMS | 693 (28.6) | 378 (27.8) | 315 (29.5) | 0.369 |
| DES | 146 (6.0) | 61 (4.5) | 85 (8.0) | <0.001 |
| Postprocedure medical therapy | ||||
| Dual antiplatelet therapy | 1972 (81.3) | 1124 (82.7) | 848 (79.4) | 0.035 |
| Lipid-lowering drugs | 1932 (79.6) | 1131 (83.3) | 801 (75.0) | <0.001 |
| Angiotensin blockers | 1330 (55.0) | 875 (64.4) | 455 (42.6) | <0.001 |
Abbreviations: BMS, bare metal stent; DES, drug-eluting stent; LDL, low-density lipoprotein; MI, myocardial infarction.
a
Continuous data are presented as the means ± standard deviation; categorical data are given as the counts (percentage).
b
Multivessel disease is defined as both femoropopliteal disease and below the knee disease.
c
Heavy calcification is defined as the presence of at least 5 mm of calcification on both sides of the vessel.